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Abstract
Coexistence of multiple chronic conditions (i.e., multimorbidity) is the most common chronic 
health problem in adults. However, clinical practice guidelines have primarily focused on patients 
with a single disease, resulting in uncertainty about the care of patients with multimorbidity. The 
American Thoracic Society convened a workshop with the goal of establishing a strategy to 
address multimorbidity within clinical practice guidelines. In this Workshop Report, we describe a 
framework that addresses multimorbidity in each of the key steps of guideline development: topic 
selection, panel composition, identifying clinical questions, searching for and synthesizing 
evidence, rating the quality of that evidence, summarizing benefits and harms, formulating 
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recommendations, and rating the strength of the recommendations. For the consideration of 
multimorbidity in guidelines to be successful and sustainable, the process must be both feasible 
and pragmatic. It is likely that this will be achieved best by the step-wise addition and refinement 
of the various components of the framework.
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Overview
Multimorbidity (i.e., coexistence of multiple chronic conditions) is a common chronic health 
problem in adults. It is associated with many undesirable consequences; for example, as the 
number of chronic conditions increases in individuals, so does the occurrence of poor 
outcomes, such as lower quality of life, decreased functional capacity, increased hospital 
readmissions, and both increased and more severe adverse effects of treatments. Clinical 
practice guidelines have almost exclusively focused on patients with a single condition. 
Uncertainty, therefore, exists regarding the evidence-based management of patients with 
multimorbidity. The American Thoracic Society (ATS) convened a workshop with the goal 
of establishing a strategy to address multimorbidity within clinical practice guidelines. Key 
conclusions from the workshop included the following:
• Clinical practice guidelines should maximize the use of therapies likely to 
benefit patients with multimorbidity, while minimizing the use of therapies that 
are either unlikely to benefit or likely to harm such patients. This is best done by 
applying a patient-centered, rather than a disease-specific, framework.
• Guidelines can focus on an index condition and one or more important coexisting 
conditions or modifying factors. Alternatively, guidelines can address a pair or 
cluster of conditions, among which no single condition is considered to be 
primary. Finally, guidelines can address multimorbidity in a more general way, 
such as guidelines addressing the coordination of care. Figure 1 illustrates these 
approaches.
• Guidelines that address an index condition and either coexisting conditions or 
modifying factors benefit from having participants with a broad range of 
experience on the guideline development panel. We suggest that the guideline 
development group include everyone involved in the care of patients with 
multimorbidity: physicians (specialists who care for the index condition, 
specialists who care for coexisting conditions, generalists), nonphysicians (e.g., 
nurses, physicians assistants, respiratory therapists), patients, caregivers, and 
other stakeholders.
• There are several reasonable approaches to identifying questions that will be 
addressed in a guideline. One approach is to specify multiple questions, each 
addressing the management of the index condition and a different coexisting 
condition. Alternatively, a single question can be developed for the index 
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condition with the intention of addressing the coexisting conditions during the 
evidence synthesis and formulation of recommendations.
• Clinical outcomes related to health benefits, harms, and burdens are used to 
assess the effects of various management options. Many outcomes are 
specifically related to the index condition; however, when addressing questions 
about the management of patients with multimorbidity, a broader spectrum of 
outcomes that includes those specifically related to common coexisting 
conditions is warranted. Selection of outcomes should be informed by patients 
who have multimorbidity and their family members or caregivers.
• Confidence in the estimated effects (i.e., quality of evidence) of an intervention 
is generally lower in the context of multimorbidity than when only a single 
condition is considered. Randomized trials provide greater confidence in 
estimated effects than observational studies; however, they are also less likely to 
include patients with multimorbidity. Therefore, guideline developers often rely 
upon observational evidence or randomized trial evidence from other populations 
to inform judgments related to patients with multimorbidity, both of which 
provide lower confidence in the estimated effects of an intervention.
• To inform judgments about whether or not to use an intervention, guideline 
developers should examine the direction and magnitude of the estimated health 
benefits and harms, the duration until each outcome is likely to occur, values and 
preferences, required resources, and the feasibility of implementing the 
intervention in individuals with multimorbidity.
• When making recommendations for patients with multimorbidity, it is important 
to identify subgroups that are more likely to benefit or be harmed by the 
recommended action owing to different baseline risk or potential interactions 
among several interventions that are likely to be used concomitantly.
• Recommendations made for patients with multimorbidity are more likely to be 
conditional (i.e., weak) compared with those targeting individuals who have only 
the index condition. This stems from the lower confidence in the estimated 
effects (i.e., the lower quality of evidence), likely higher cost and greater 
resources needed to deliver certain interventions to patients with multimorbidity, 
and more variability in values and preferences among patients with 
multimorbidity. This uncertainty will hopefully help to stimulate and prioritize 
future studies.
Introduction
Multimorbidity (i.e., coexistence of multiple chronic conditions) has been described as the 
most common chronic health problem in adults (1). Multiple studies report that more than 
25% of all adults and in excess of 65% of Medicare beneficiaries have two or more chronic 
conditions (2–10). Thus, multimorbidity is the usual patient experience among older adults. 
As examples, asthma and chronic obstructive pulmonary disease (COPD) are the lone 
conditions in only 4 and 3% of Medicare beneficiaries, respectively (11). Among those with 
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asthma, 21% have one to two coexisting conditions, 30% have three to four coexisting 
conditions, and 45% have more than five coexisting conditions (11). Among those with 
COPD, 18% have one to two coexisting conditions, 30% have three to four coexisting 
conditions, and 49% have more than five coexisting conditions (11); the pattern of 
coexisting conditions in patients with COPD also varies according to age (Table 1).
The high prevalence of multimorbidity has many undesirable consequences. Healthcare 
expenditures and hospital readmissions are directly related to the number of chronic 
conditions (11). In addition, cumulatively higher numbers of chronic conditions correlate 
directly with incrementally poorer clinical outcomes, including mortality, poor functional 
status, hospitalizations, hospital readmissions (Figure 2), and adverse drug events.
Recognizing the importance of multimorbidity, the U.S. Department of Health and Human 
Services (DHHS) created a working group in 2009, which subsequently released a strategic 
framework on multimorbidity in 2010 (12). One of the goals of the framework was to 
provide better tools and information to healthcare, public health, and social service workers. 
Within this domain, the DHHS included an objective and initiated a concerted effort to 
address multimorbidity in clinical practice guidelines.
Clinical practice guidelines have an important role in guiding how we provide care and share 
decision making with patients; however, their applicability for real-world care is limited, 
because they have been largely developed for and emphasize a single-condition perspective 
(13). As a result, such single-morbidity guidelines seldom account for the uncertain benefit 
and potential harm of numerous simultaneous treatments, the possibility of exacerbating a 
particular condition by treating a coexisting one, or the complexity and treatment burden 
arising from simultaneously trying to apply multiple clinical guidelines for several 
conditions (1, 14, 15).
The ATS participated in a DHHS/Institute of Medicine meeting on clinical practice 
guidelines and multimorbidity in May 2012 (16). As follow up to that meeting, the ATS 
launched its own initiative to address multimorbidity in its clinical practice guidelines. The 
initial step was to convene a workshop in October 2014 with the goal of establishing a 
framework to address multimorbidity in ATS clinical practice guidelines for pulmonary 
disease, critical illness, and sleep medicine. This report describes the proceedings and 
conclusions from the workshop. The framework will serve as the basis of future steps to 
consider multimorbidity in its guidelines.
Methods
The ATS Documents Development and Implementation Committee selected co-chairs 
(M.K.G., J.A.K., and K.C.W.) to lead a workshop with the goal of developing a framework 
that will be used during the development of future ATS guidelines. Workshop participants 
included an interdisciplinary group of clinicians, researchers, and guideline methodologists 
within ATS, and individuals with experience working with other professional societies 
(C.M.B., R.A.G., and R.M.R.). The workshop proposal was approved and funded by the 
ATS Board of Directors.
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The workshop was convened in Orlando, Florida on October 17, 2014. Speakers (C.M.B., 
J.L.B., R.A.G., and R.M.R.) outlined the scope of the problem, described a potential 
framework, discussed potential challenges in applying the framework, and described another 
professional society’s experience addressing multimorbidity in guidelines. Each talk was 
followed by discussion among the entire panel of participants. After the talks, the 
participants were divided into two groups for breakout sessions to discuss the application of 
the framework using different index conditions as examples.
The initial draft of the Workshop Report was authored by the co-chairs and speakers. The 
other panel members then reviewed and edited the draft report. The Workshop Report 
underwent several cycles of external peer review and revisions, followed by review and 
approval by the ATS Board of Directors.
Addressing Multimorbidity in Guidelines
Framework
The workshop participants used a framework developed by Katrin Uhlig and colleagues (17) 
as the foundation upon which to inform their judgments. The Uhlig framework was highly 
regarded by the workshop participants for several reasons. First, it addresses most of the 
steps of guideline development, including selecting the topic, assembling the panel, 
choosing and formulating the questions, reviewing and synthesizing the evidence, appraising 
the quality of evidence, summarizing the benefits and harms, and formulating the 
recommendations and rating their strength. Second, it shares the belief of ATS that clinical 
practice guidelines should maximize patient-centered care by incorporating patients’ and 
caregivers’ perspectives, recognizing their need for information, enhancing prevention and 
health promotion, and facilitating a continuing relationship between patients and clinicians.
Topic selection—There are numerous ways to address multimorbidity in clinical practice 
guidelines. Guidelines can focus on an index condition and one or more important coexisting 
conditions or modifying factors, and then address their combined management. 
Alternatively, guidelines can address a pair or complex of conditions, among which no one 
condition is primary. A potential downside to this approach is that it might leave other 
important combinations unaddressed. Finally, guidelines can address multimorbidity in a 
non–disease-specific way, such as guidelines addressing the coordination of care or self-
management (17). These approaches are illustrated in Figure 1.
Clinical practice guidelines will be most useful if they address combinations of coexisting 
conditions that are common and the interactions of which are important or uncertain. The 
latter includes interactions in which the index condition and the coexisting conditions 
aggravate or ameliorate one another (e.g., COPD and heart failure), treatment of the index 
condition affects the coexisting conditions (e.g., the impact of long-term steroid therapy for 
sarcoidosis on diabetes and osteoporosis), and/or interactions between the treatments of the 
index condition and treatment of the coexisting conditions (i.e., polypharmacy). When 
deciding which interactions to address, it is helpful to look for interactions that affect 
outcomes that matter to patients, such as symptoms or functional impairment. Data 
regarding the frequency of various combinations of coexisting conditions may derive from 
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epidemiological studies and cross-sectional studies of databases of diagnostic codes and 
administrative claims; data regarding interactions among coexisting conditions are more 
scarce, but may derive from observational studies that follow individuals with an index 
condition or a combination of coexisting conditions and measure adverse outcomes 
attributable to condition–condition, condition–medication, or medication–medication 
interactions. An appropriate next step for guideline developers who want to address 
multimorbidity is to operationalize these concepts, a process that will necessarily be iterative 
to ensure that it is feasible.
Guideline development group composition—It is well accepted that a guideline 
development group should include clinicians from specialties relevant to the index condition. 
As an example, a guideline on lung cancer might include a pulmonologist, thoracic surgeon, 
medical oncologist, radiation oncologist, and palliative care clinician. To address 
multimorbidity, however, even broader representation may be necessary. This may include 
specialists who manage each of the coexisting conditions, a generalist (i.e., a geriatrician, 
internist, or family physician) who frequently coordinates and balances a patient’s care 
among many specialists, and nonphysicians (17). Examples of relevant nonphysician 
participants include healthcare professionals (e.g., nurses, physicians’ assistants, and 
respiratory therapists), patients, caregivers, and others who can provide insights related to 
values and preferences relevant to decision making (17).
Clinical questions—The clinical questions addressed in guidelines are typically 
formulated using the population, intervention, comparator, outcomes (PICO) format. One 
possible approach to formulating questions that incorporate multimorbidity is to ask multiple 
questions, each addressing the index condition and a different coexisting condition or 
clusters of chronic conditions. Alternatively, a single question related to the index condition 
can be asked with the plan to address coexisting conditions as subgroup considerations. The 
impact of these options on the formulation of recommendations is discussed in greater detail 
below.
An important part of deriving the PICO questions is selection of the outcomes. Outcomes 
used in guideline development are generally related to potential health benefits and harms 
that are specific to the index condition. When addressing patients with multimorbidity, 
however, consideration of a broader spectrum of outcomes may be warranted (17). 
Outcomes related to both the index condition and common coexisting conditions should be 
considered. As an example, consider a question about whether or not to prescribe a 
medication to a patient who has COPD. A guideline that addresses multimorbidity might 
consider not only COPD-specific outcomes, such as dyspnea, exercise capacity, and the 
frequency of COPD exacerbations, but also outcomes, such as the frequency of myocardial 
infarction, coronary revascularization, sudden cardiac death, and hypercholesterolemia, 
because ischemic heart disease and hyperlipidemia are conditions that commonly coexist 
with COPD and may be affected by its treatments.
Outcomes that are specific for neither the index condition nor coexisting conditions should 
also be included; as an example, functional status is a nonspecific outcome. The timeframe 
for outcomes to develop should also be considered, as long-term outcomes may be irrelevant 
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for decision making if the population of interest has a short life expectancy. Finally, 
outcomes should be realistic; return to full-time employment would not be a realistic 
outcome for those anticipated to have physical or cognitive changes that would make this 
unrealistic.
Searching and selecting evidence—Evidence syntheses generally prioritize the 
highest-quality evidence in the form of existing systematic reviews and randomized trials. 
Ideally, studies would report treatment–comorbidity interactions or supply sufficient data to 
perform quantitative or qualitative summaries of trends (18). Given the paucity of 
randomized trial data with sufficient inclusivity of those with multimorbidity (19–24), 
evidence searches should anticipate including nonrandomized studies that estimate the 
differential effects and safety among those with comorbidity.
Summarizing the evidence—Explicit delineation of health benefits and harms, values 
and preferences, implementation issues, and resource requirements (when available) allows 
guideline development groups to weigh the desirable consequences of an intervention with 
the undesirable consequences. Guideline developers should ask whether these factors and 
the resulting balance of desirable and undesirable consequences are the same or different 
among individuals with multimorbidity compared with the populations from which the 
estimates were derived (17). In addition to the usually serious indirectness of the evidence, 
individuals with multimorbidity often have a different baseline risk for certain outcomes. 
Thus, relative effects derived from studies among patients with single conditions are more 
likely to be correct among patients with multimorbidity than absolute effects (25, 26). 
Guideline panels should be cautious about the assumption of fairly constant relative effects, 
however, because disease and treatment interactions may substantially modify relative risks. 
Guideline developers should always seek estimates of the baseline risk of outcomes among 
populations with characteristics closest to that for which a recommendation is being made. 
This is especially important when making recommendations for patients with 
multimorbidity. Such information may be found in separate observational studies that 
provide relevant prognostic information (27).
Guideline developers should estimate the required duration for a particular treatment to 
achieve the desired benefit. In addition, careful consideration of important trade-offs over 
time is imperative. One is less likely to recommend a potentially harmful, burdensome, or 
expensive intervention if the benefit from that intervention is unlikely to be realized during 
the patient’s lifetime. This latter consideration is not different from similar decisions for 
patients with single conditions, but is likely to be significantly more challenging to estimate 
among patients with multimorbidity. As an example, guidelines recommend against low-
dose computed tomography screening for lung cancer among individuals with severe 
comorbidities that limit life expectancy, because the benefit of screening (preventing death 
from lung cancer) is unlikely to be realized if the patient is likely to die in a short timeframe 
from another cause.
The values and preferences that patients assign to particular outcomes (e.g., reduction of 
symptoms versus the risk of side effects) and the interventions themselves (e.g., anxiety, 
burden, or cultural attitudes toward some health interventions) are likely to be more variable 
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among patients with multimorbidity than among those with single health problems. 
Acceptance and tolerance of multiple nonspecific symptoms may be more common as a 
baseline state among patients with multimorbidity. Resources required for implementation of 
an intervention and the effect of an intervention on health inequities may similarly be more 
variable among patients with multimorbidity compared with patients with single health 
problems. Such variability should be summarized when available, because it may 
substantially influence the acceptability of interventions to various stakeholders (patients, 
caregivers, clinicians, third party payers, etc.).
Rating the quality of evidence—The quality of evidence (also referred to as certainty of 
evidence) indicates the confidence that the estimated effect of an intervention is correct. 
There are many strategies for rating the quality of evidence, but the ATS and many other 
guideline developers have adopted the Grading of Recommendations, Assessment, 
Development, and Evaluation approach. With this approach, the quality of the body of 
evidence for each outcome is determined by the study design, risk of bias, directness of the 
available evidence, precision of the estimate, consistency of the effects across studies, 
likelihood of publication bias, magnitude of an effect, presence or absence of a dose–effect 
relationship, and effect of plausible residual confounding. The quality of evidence rating is 
often lower when evidence is applied to individuals with multimorbidity than when the same 
body of evidence is applied to individuals with single conditions. There are many reasons for 
this, but the two most common are study design and indirectness.
With respect to study design, patients with multimorbidity are less likely to be included in 
randomized trials and, therefore, the evidence about treatment effects in this population 
often comes only from observational studies. Although observational studies are generally 
more inclusive than randomized trials, they are usually at substantially greater risk of bias. 
The frequent exclusion of patients with multimorbidity from randomized trials was 
illustrated by a study that reported that more than 30% of COPD trials excluded patients 
who: were receiving supplemental oxygen or oral steroid therapy; had coronary artery 
disease, musculoskeletal disease, lung disease other than COPD, or other unspecified serious 
coexisting diseases; were younger than 40 years or older than 65 years of age; or were 
unable to exercise for unspecified reasons (19).
With respect to indirectness, exclusion of patients with multimorbidity from randomized 
trials means that the mix of coexisting conditions in patients who are studied in randomized 
trials may be different than in patients typically seen in routine clinical practice. This 
indirectness lowers confidence that the estimated effects used to inform the recommendation 
reflect the actual effects of the intervention in the population for which the recommendation 
is intended (28, 29). The possibility that effects differ between the studied populations and 
the population for which the recommendation is intended stems from the difference in health 
status (individuals with multiple coexisting health problems tend to have poorer health status 
than individuals with single conditions) and the difference in the number and type of 
cointerventions (individuals with single conditions usually receive fewer concomitant 
treatments than individuals with multiple conditions).
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Another source of indirectness is related to the fact that dosing or route of administration of 
certain interventions may be different between patients with a single health problem 
compared with patients with multimorbidity (e.g., there may be a need to reduce the 
preferred dose of a medication or choose an alternative agent to avoid drug–drug 
interactions). For instance, interactions among several interventions used in those with 
multiple health problems may reduce or increase their relative effect on certain outcomes 
compared with when those same interventions are used separately.
Although not as common as risk of bias and indirectness, imprecision (i.e., wide confidence 
intervals) may also contribute to lower quality of evidence. Outcomes estimated for patients 
with specific comorbidities frequently derive from subgroup analyses performed within 
studies that enrolled patients with an index condition. The subgroups are smaller, with fewer 
events than the entire study population, and, therefore, the estimated effects of the subgroups 
tend to have wider confidence intervals. Criteria that suggest that a subgroup effect is valid 
include the following: (1) the effect is statistically significant; (2) the effect is consistent 
across studies; (3) the subgroup was defined a priori and there is a limited number of 
subgroups; (4) the effect is biologically plausible; and (5) the effect is based upon a within-
study comparison (30).
Formulating recommendations and rating their strength—Guidelines recommend 
an intervention if its desirable consequences outweigh its undesirable consequences. Panels 
make this decision by considering the following factors: the balance of health benefits versus 
harms and burdens; the quality of the available evidence; the values and preferences of those 
affected; required resources; feasibility; acceptability; and impact on health inequities. In 
contrast, guidelines recommend against an intervention if the undesirable consequences 
outweigh the desirable consequences.
When recommendations are made for patients with multimorbidity, there are several 
reasonable approaches, which are related to the approach to identifying questions described 
above. If the guideline panel decided to ask multiple questions, each addressing the index 
condition and a different coexisting condition or clusters of chronic conditions, then the 
panel may provide a recommendation for each of the questions. Alternatively, if the 
guideline panel decided to ask a single question related to the index condition with the plan 
to address coexisting conditions as subgroups considerations, then the panel may either: (1) 
provide a single recommendation that is applicable to most patients, followed by a 
description of additional considerations related to coexisting conditions; or (2) provide a 
single recommendation that is applicable to most patients, followed by additional 
recommendations for coexisting conditions. The preferred approach will depend upon the 
context, such as the nature, number, and prevalence of coexisting conditions (17), as well as 
the clarity of the final presentation of recommendations. Regardless of the approach taken, it 
is most important to identify subgroups that are more likely to benefit from or be harmed by 
the recommended action. Patients with multimorbidity may have an increased likelihood of 
benefiting from certain interventions due to their greater baseline risk of an adverse 
outcome; however, they may also be more likely to be harmed due to potential interactions 
among several interventions likely to be used concomitantly.
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The strength of a recommendation indicates the degree of certainty among the guideline 
development group’s members that the desirable consequences of an intervention outweigh 
the undesirable consequences. When a guideline panel is certain, they make a strong 
recommendation; when they are uncertain, they make a conditional (i.e., weak) 
recommendation. In other words, a conditional recommendation implies that the majority of 
well informed people in such situations would choose the recommended course of action, 
but a substantial number would not. Recommendations for patients with multimorbidity are 
more likely to be conditional than recommendations targeting individuals who have only the 
index condition, because of the uncertainties about the magnitude of effects, directness of 
the information, and other factors discussed previously. Conditional recommendations may 
stimulate and prioritize future studies among patients with multiple chronic conditions, 
including studies employing a comparative effectiveness or implementation science 
framework.
Illustrative Case Example
Consider the example of clinical practice guidelines that address the evaluation of 
incidentally identified pulmonary nodules. To guide shared decision making, the guideline 
panel should consist of those who detect the nodules, those who order the imaging studies 
and then act upon the results, and those with whom a patient with a newly detected nodule 
may consult. Hence the guideline development group might include a radiologist, primary 
care clinician, hospitalist, nurse practitioner, physician’s assistant, pulmonologist, and 
thoracic surgeon. Inclusion of a patient with multimorbidity, a caregiver, and at least one 
patient who has been evaluated for incidentally detected pulmonary nodules is also 
important. The perspective of the patient should be carefully considered; as an example, if 
the patient is someone whose life was saved by screening and subsequent curative resection 
of a malignant nodule, a second patient who experienced complications from unnecessary 
diagnostic testing should also be added to balance the views of the first patient.
Multimorbidity is common among patients with incidentally discovered pulmonary nodules 
according to the collective clinical experience of the workshop participants. During or before 
group composition, the most common coexisting conditions and the coexisting conditions 
most likely to affect the management of pulmonary nodules should be determined. The 
former may include COPD, heart failure, tobacco dependence, ischemic heart disease, 
hypertension, and depression, whereas the latter may include atrial fibrillation and venous 
thromboembolic disease (i.e., patient taking anticoagulants), obesity (i.e., increased 
technical difficulty of diagnostic procedures), and limited life expectancy due to any cause 
(i.e., terminal disease, advanced age). To address these coexisting conditions, a geriatrician, 
cardiologist, and psychiatrist may be added to the guideline development group.
The assembled guideline development group’s first task is to develop the PICO questions 
that will form the basis of the systematic review and then be answered by a 
recommendation. Among the possible approaches—(1) developing multiple PICO questions 
that each address patients with lung nodules and a different coexisting condition, or (2) 
developing a single PICO question in anticipation of addressing coexisting conditions via 
either remarks or multiple recommendations—option 2 is the preferred approach for these 
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guidelines, because the number of common coexisting conditions (i.e., COPD, heart failure, 
tobacco dependence, ischemic heart disease, hypertension, and depression) and coexisting 
conditions that may influence management (i.e., atrial fibrillation, venous thromboembolic 
disease, obesity, and old age) is so large that option 1 is impractical.
The evidence synthesis should evaluate the types of patients enrolled in each study selected 
during the systematic review. Of particular interest is whether the studies excluded patients 
with the chronic coexisting conditions of interest. This evaluation lends itself to sensitivity 
analyses (i.e., whether results are different among the studies that excluded patients with a 
coexisting condition of interest than among the studies that did not exclude patients with that 
coexisting condition). It also facilitates recognition of whether the population of interest is 
the same as the population studied (i.e., whether there is indirectness of the population) and 
whether the results are consistent across studies.
After the evidence synthesis, the guideline development group will begin to formulate its 
recommendations based upon consideration of the balance of benefits versus harms and 
burdens, quality of evidence, patient values and preferences, cost, and resource use. The 
potential benefit of evaluating incidentally detected lung nodules is decreased mortality due 
to lung cancer, whereas the potential harms include the complications of diagnostic testing 
(e.g., pneumothorax or bleeding after biopsy), consequences of false-positive results (e.g., 
unnecessary additional diagnostic testing or treatment), and consequences of false-negative 
results (i.e., false reassurance, delayed diagnosis). The balance of potential benefits versus 
harms may be substantially affected by coexisting conditions. As examples, patients with a 
limited life expectancy have a less favorable benefit-to-harm ratio due to both decreased 
benefit and increased harm, whereas patients taking anticoagulants or who are obese have a 
less favorable benefit-to-harm ratio due to increased risk of harms alone. It is preferable to 
make separate recommendations for each coexisting condition or cluster of conditions, 
because the different courses of actions will be more apparent to readers.
Other Organizations’ Experiences
The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) has 
already begun to consider multimorbidity in its professional society guidelines, which 
provides an opportunity for other guideline developers to learn from their experiences (31). 
Among the steps taken by the AAO-HNS to address multimorbidity in its guidelines, 
perhaps the most successful has been routine establishment of guideline development groups 
in which generalist physicians (e.g., pediatricians, family physicians, and internists), non–
otolaryngology specialists (e.g., radiologists, pathologists, and anesthesiologists), and 
nonphysicians (e.g., nurses, audiologists, speech pathologists, consumers, physician 
assistants, and researchers) outnumber otolaryngologists. The generalists in particular tend 
to be helpful in keeping the guideline development group aware of coexisting conditions and 
modifying factors (e.g., asthma and sinusitis) throughout the development process. Diverse 
guideline development groups appear to balance biases, build support for the guidelines, and 
increase the likelihood that all relevant scientific evidence will be located, that practical 
aspects will be addressed, that debate will be robust, and that group members will learn from 
one another about different perspectives on multimorbidity.
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The AAO-HNS has observed that many clinicians do not consider the common coexisting 
conditions that may influence treatment choices. To address this, the organization routinely 
provides statements in its guidelines, such as “clinicians should assess the patient with 
chronic or recurrent sinusitis for multimorbidity that would modify management, such as 
asthma, cystic fibrosis, an immunocompromised state, and ciliary dyskinesia” (32). Such 
statements explicitly alert readers to common coexisting conditions and provide the 
foundation for subsequent discussions in the text. The statements also set the stage for 
recommendations that either target patients with such coexisting conditions or are followed 
by descriptions of caveats associated with coexisting conditions.
Broad peer review of guidelines by many types of stakeholders allows the guidelines to be 
reviewed from many perspectives. For example, AAO-HNS routinely sends its guidelines to 
more than 40 external peer reviewers for consideration. This approach is particularly helpful 
in the context of multimorbidity, because each chronic condition may prompt a unique 
perspective worthy of consideration (e.g., the perspective of a cardiologist is likely different 
than that of a pulmonologist for a question addressing the management COPD exacerbations 
in patients with coexisting ischemic cardiomyopathy) and should include patient and 
caregiver input.
Although guideline developers, such as the AAO-HNS, have made positive strides in 
addressing multimorbidity, there are ways in which the process can be improved. As 
examples, it would be helpful to precede each guideline with research identifying the most 
common coexisting conditions and to incorporate a process for considering multimorbidity 
into each step of guideline development. Regardless of a guideline developer’s initial steps, 
many hope to eventually address multimorbidity as the main focus, rather than something 
that accompanies an index condition.
The AAO-HNS is not the only professional society that has begun to address multimorbidity 
in its guidelines. The American Heart Association and American College of Cardiology have 
developed their own framework for addressing multimorbidity (33), and have begun to 
include new content related to multimorbidity in guideline updates (34). The American 
Society of Clinical Oncology has addressed multimorbidity in some of its most recent 
guidelines (35), and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
Stretegy address multimorbidity. GOLD says that COPD rarely exists alone, coexisting 
conditions are often neither diagnosed nor treated, frequent coexisting conditions should be 
actively sought, and coexisting conditions in patients with COPD should be managed the 
same as in patients who do not have COPD (36). Although we acknowledge that, in many 
circumstances, management of the coexisting condition is the same whether the patient does 
or does not have COPD, we believe that the primary reason that guidelines should address 
multimorbidity is to systematically and rigorously determine whether or not 
recommendations should vary depending upon the constellation of coexisting conditions.
Challenges and Future Plans
The framework for addressing multimorbidity in clinical practice guidelines described above 
will require additional effort from guideline developers—additional guideline development 
group members will need to be recruited and coordinated, evidence syntheses will need to be 
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broader and consider more observational data and outcomes, and decision making (i.e., 
formulating and grading recommendations) will be more complex. Guideline development 
bodies should strive to determine which chronic coexisting conditions or combinations of 
conditions are most important to address, which require measuring the prevalence of various 
conditions, influence on management, and/or influence on outcomes. More diverse 
representation in the guideline development group requires that resources must be secured to 
support a larger and more diverse guideline panel, which requires commitment from 
organizational leadership and buy-in from clinical experts. Methods need to be established to 
measure the heterogeneous effects of interventions across patients with different 
combinations of chronic conditions, the baseline risk of outcomes among patients with 
various combinations of chronic conditions, and the time horizon for benefits and harms to 
accrue. Professional societies and federal scientific funding agencies should encourage and 
fund studies that specifically evaluate therapeutic efficacy in the context of varying strata of 
prespecified baseline risk. Finally, testing and validation of the various components of the 
framework by guideline methodologists will be necessary to determine essential steps and 
demonstrate measurable benefit in effectiveness, implementation, and, ultimately, patient 
outcomes. We recommend that guideline developers who are beginning to develop a process 
for addressing multimorbidity in their guidelines adopt a test case to operationalize the 
concepts in this Workshop Report. This may involve a guideline directed at adult or pediatric 
patients, because the concepts included in the framework are equally applicable to pediatric 
patients with multimorbidity.
Traditional guidelines directed at an index condition can play an important role in addressing 
multimorbidity during the transition to the more multimorbidity-focused process described 
above. During the evidence synthesis, guideline developers should assess and summarize 
evidence from subgroups of patients who have the index condition and important coexisting 
conditions. Then, specific recommendations should be made for each combination of the 
index condition and a coexisting condition, if appropriate. This can be implemented 
immediately, providing much-needed guidance for managing patients with multiple 
coexisting conditions.
Conclusions
For the consideration of multimorbidity in guidelines to be successful and sustained, it must 
be both feasible and pragmatic. It is likely that this will be best achieved by the step-wise 
addition, refinement, and codification of the various components of the framework. To 
facilitate development and testing of this methodology, the ATS Documents Development 
and Implementation Committee plans to work with ATS leadership to select one or more 
guideline topics that address interactions between an index condition and its important 
chronic coexisting conditions. The guideline development groups will be composed of 
individuals that include specialists in the index condition, specialists in the coexisting 
conditions, generalists, nurses, other allied health professionals, patients, caregivers, and 
other stakeholders. The guideline development groups will be reminded to select outcomes 
of importance to patients, including those that may result from the coexisting conditions. 
The evidence syntheses will be required to describe the inclusion and exclusion criteria of 
the selected studies, the effects of multimorbidity on outcomes, and the directness of the 
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evidence. Finally, guideline development will address the effect of chronic coexisting 
conditions via separate recommendations or in the remarks that follow each 
recommendation. After the completion of such guidelines, the success in addressing 
multimorbidity will be evaluated and the steps modified accordingly.
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Figure 1. 
Considering multimorbidity in clinical practice guidelines. There are numerous ways to 
address multimorbidity in clinical practice guidelines. (A) Guidelines can focus on an index 
condition and pick one or more important coexisting conditions to address their combined 
management. (B) Guidelines can address a pair of conditions, in which neither condition is 
the primary condition. A potential downside to this approach is that it might leave other 
important combinations unaddressed. (C) Guidelines can address multimorbidity in a non–
disease-specific way, such as guidelines addressing the coordination of care or self-
management (adapted by permission from Reference 17).
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Figure 2. 
The prevalence of multimorbidity and its association with readmissions among U.S. 
Medicare beneficiaries (Reproduced by permission from Reference 11).
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Table 1
The Top 10 Most Common Co-occurring Chronic Conditions among Medicare Beneficiaries with Chronic 
Obstructive Pulmonary Disease (n = 3,850,265), 2012
%
Beneficiaries under 65 yr of age (n = 688,542)
 COPD prevalence 11.0
 Top 10 comorbidities
  Hypertension 70.7
  Hyperlipidemia 52.3
  Depression 47.3
  Ischemic heart disease 42.8
  Diabetes 42.5
  Arthritis (RA/OA) 42.3
  Anemia 36.3
  Heart Failure 30.3
  Chronic kidney disease 24.7
  Asthma 23.4
Beneficiaries 65 yr of age and older (n = 3,161,723)
 COPD prevalence 11.3
 Top 10 comorbidities
  Hypertension 81.4
  Hyperlipidemia 61.3
  Ischemic heart disease 57.6
  Anemia 45.4
  Arthritis (RA/OA) 44.1
  Heart failure 42.7
  Diabetes 38.6
  Chronic kidney disease 34.3
  Depression 26.6
  Alzheimier’s Disease 20.2
Definition of abbreviations: COPD = chronic obstructive pulmonary disease; OA = osteoarthritis; RA = rheumatoid arthritis. Prepared by the 
Centers for Medicare and Medicaid Services (CMS)/Office of Information Products and Data Analytics on October 6, 2014. Data Source: CMS 
administrative claims data, January 2012–December 2012, from the Chronic Condition Warehouse (https://www.ccwdata.org).
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